[Correspondence] Alteplase for ischaemic stroke

Roger Shinton's Correspondence (Aug 23, p 659) called into question the evidence supporting the safe use of alteplase in patients with acute ischaemic stroke. Ian Hudson, of the Medicines and Healthcare Products Regulatory Agency (MHRA), responded to this Correspondence by convening an expert working group to review the benefits and risks of this drug. A review of reports of spontaneous adverse drug reactions (ADR) should inform this query, but a substantial level of under-reporting might restrict its use.
Source: LANCET - Category: Journals (General) Authors: Tags: Correspondence Source Type: research